FDA staff question efficacy of GSK’s Nucala for COPD
admin 24th July 2018 Uncategorised 0US regulatory advisors are questioning the effectiveness of GlaxoSmithKline’s biologic Nucala as a treatment for patients experiencing a sudden worsening of chronic obstructive pulmonary disorder (COPD).
More: FDA staff question efficacy of GSK’s Nucala for COPD
Source: News